Leap Therapeutics Files Proxy Statement Supplement

Ticker: CYPH · Form: DEFA14A · Filed: May 16, 2024 · CIK: 1509745

Leap Therapeutics, INC. DEFA14A Filing Summary
FieldDetail
CompanyLeap Therapeutics, INC. (CYPH)
Form TypeDEFA14A
Filed DateMay 16, 2024
Risk Levellow
Pages3
Reading Time4 min
Sentimentneutral

Sentiment: neutral

Topics: proxy-statement, shareholder-meeting, regulatory-filing

Related Tickers: LEAP

TL;DR

LEAP filed proxy docs, shareholders get more info before voting.

AI Summary

Leap Therapeutics, Inc. (LEAP) filed a DEFA14A, which is a supplement to its proxy statement. This filing provides additional materials related to the company's upcoming annual meeting of stockholders. The supplement does not contain specific financial figures or proposals but serves to provide updated or additional information to shareholders before they vote.

Why It Matters

This filing informs shareholders of Leap Therapeutics about additional information relevant to their upcoming vote at the annual meeting, ensuring they have all necessary details for informed decision-making.

Risk Assessment

Risk Level: low — This filing is a routine proxy statement supplement and does not contain new financial information or significant corporate actions that would inherently increase risk.

Key Players & Entities

FAQ

What type of filing is this DEFA14A?

This filing is a DEFA14A, specifically a 'Definitive Additional Materials' supplement to the proxy statement for Leap Therapeutics, Inc.

Who is the registrant for this filing?

The registrant is LEAP THERAPEUTICS, INC.

What is the purpose of a DEFA14A filing?

A DEFA14A filing is used to provide definitive additional materials to shareholders, supplementing an earlier proxy statement, often before a shareholder meeting.

When was Leap Therapeutics, Inc. incorporated?

The filing indicates the state of incorporation is Delaware (DE).

What was Leap Therapeutics, Inc.'s former company name?

Leap Therapeutics, Inc.'s former company name was Dekkun Corp, with a name change date of January 7, 2011.

Filing Stats: 984 words · 4 min read · ~3 pages · Grade level 9.9 · Accepted 2024-05-15 19:15:53

Filing Documents

AND “FOR” ITEMS 2, 3 AND 4

ITEM 1 AND “FOR” ITEMS 2, 3 AND 4. 188272 Leap Therapeutics Proxy Card Rev3 Front CONTROL NUMBER FOLD HERE • DO NOT SEPARATE • INSERT IN ENVELOPE PROVIDED (1) James Cavanaugh (2) Douglas E. Onsi (3) Christian Richard (4) Richard Schilsky 2. Advisory vote on executive compensation paid to named executive officers (“Say-on-Pay Proposal”). 3. To approve an amendment to the Leap Therapeutics, Inc. 2022 Equity Incentive Plan (“EIP Proposal”). FOR AGAINST ABSTAIN FOR AGAINST ABSTAIN FOR AGAINST ABSTAIN 4. Ratification of the appointment of EisnerAmper LLP, an independent registered public accounting firm, as our independent auditors for the year ending December 31, 2024. 1. Election of Directors PLEASE DO NOT RETURN THE PROXY CARD IF YOU ARE VOTING ELECTRONICALLY OR BY PHONE. INTERNET/MOBILE – www.cstproxyvote.com Use the Internet to vote your proxy. Have your proxy card available when you access the above website. Follow the prompts to vote your shares. Vote at the Meeting – If you plan to attend the virtual online annual meeting, you will need your 12 digit control number to vote electronically at the annual meeting. To attend: https://www.cstproxy.com/leaptx/2024 MOBILE VOTING On your Smartphone/Tablet, open the QR Reader and scan the below image. Once the voting site is displayed, enter your Control Number from the proxy card and vote your shares. PHONE – 1 (866) 894-0536 Use a touch-tone telephone to vote your proxy. Have your proxy card available when you call. Follow the voting instructions to vote your shares. MAIL – Mark, sign and date your proxy card and return it in the postage-paid envelope provided. Your phone or Internet vote authorizes the named proxies to vote your shares in the same manner as if you marked, signed and returned your proxy card. Votes submitted electronically over the Internet or by telephone must be received by 11:59 p.m., Eastern Time, on July 1, 2024. . Y

View Full Filing

View this DEFA14A filing on SEC EDGAR

View on Read The Filing